+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Towa Pharmaceutical Co Ltd (4553) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 40 Pages
  • August 2024
  • GlobalData
  • ID: 5846110
Towa Pharmaceutical Co Ltd (4553) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Towa Pharmaceutical Co Ltd (Towa Pharmaceutical) is a manufacturer and seller of pharmaceutical products. It develops, manufactures, and distributes generic drugs. The company offers products such as vitamins, antibiotics and other drugs. Towa offers products in the therapeutic areas of gastroenterology, neurology, allergy, bacterial infections, chemotherapy, metabolism, hormone drugs, cardiology and respiratory. The company uses its proprietary technologies such as Ractab, a unique formulation technology for orally disintegrating (OD) tablets. The company also offers drug packaging and testing programs. It offers products in the form of tablets, capsules, injectables, patches, eye drops and others. The company sells its products through medical representatives. It operates through its sales offices in Sapporo, Aomori, Morioka, Sendai, Nagaoka, Nagano, Osaka, Tottori, and Nagasaki, among others. Towa is headquartered in Kadoma, Osaka, Japan.

Towa Pharmaceutical Co Ltd Key Recent Developments

  • Aug 08, 2024: Towa Pharmaceutical Announces Consolidated Financial Results for the Three Months Ended June 30, 2024
  • May 22, 2024: Towa Pharmaceutical Notice of Changes in Officers

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Towa Pharmaceutical Co Ltd - Key Facts
  • Towa Pharmaceutical Co Ltd - Key Employees
  • Towa Pharmaceutical Co Ltd - Major Products and Services
  • Towa Pharmaceutical Co Ltd - History
  • Towa Pharmaceutical Co Ltd - Company Statement
  • Towa Pharmaceutical Co Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Towa Pharmaceutical Co Ltd - Business Description
  • Geographical Segment: Domestic
  • Performance
  • Geographical Segment: Overseas
  • Performance
  • R&D Overview
  • Towa Pharmaceutical Co Ltd - Corporate Strategy
  • Towa Pharmaceutical Co Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Towa Pharmaceutical Co Ltd - Strengths
  • Towa Pharmaceutical Co Ltd - Weaknesses
  • Towa Pharmaceutical Co Ltd - Opportunities
  • Towa Pharmaceutical Co Ltd - Threats
  • Towa Pharmaceutical Co Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Towa Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 08, 2024: Towa Pharmaceutical Announces Consolidated Financial Results for the Three Months Ended June 30, 2024
  • May 22, 2024: Towa Pharmaceutical Notice of Changes in Officers
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Towa Pharmaceutical Co Ltd, Key Facts
  • Towa Pharmaceutical Co Ltd, Key Employees
  • Towa Pharmaceutical Co Ltd, Major Products and Services
  • Towa Pharmaceutical Co Ltd, History
  • Towa Pharmaceutical Co Ltd, Subsidiaries
  • Towa Pharmaceutical Co Ltd, Key Competitors
  • Towa Pharmaceutical Co Ltd, Ratios based on current share price
  • Towa Pharmaceutical Co Ltd, Annual Ratios
  • Towa Pharmaceutical Co Ltd, Interim Ratios
  • Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Towa Pharmaceutical Co Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Towa Pharmaceutical Co Ltd, Performance Chart (2020 - 2024)
  • Towa Pharmaceutical Co Ltd, Ratio Charts
  • Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Towa Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sumitomo Pharma Co Ltd
  • Daito Pharmaceutical Co Ltd
  • Chugai Pharmaceutical Co Ltd
  • Nxera Pharma Co Ltd
  • ASKA Pharmaceutical Holdings Co Ltd